Amgen to buy Celgene's psoriasis drug Otezla for $13.4 billionChristian Fernsby ▼ | August 26, 2019
Amgen said on it would buy Celgene’s psoriasis drug Otezla for $13.4 billion in cash.
Acquisition This is clearing the way for Bristol-Myers Squibb to go ahead
Topics: Amgen Celgene
The deal for Otezla and certain related assets and liabilities is valued at $11.2 billion, net of the present value of $2.2 billion in future cash tax benefits.
Bristol-Myers Squibb Co in June offered to sell Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion deal. ■